A silicone pressure sensitive adhesive with amphiphilic copolymers for maintaining adhesion in a moist environment. The amphiphilic copolymers for silicone adhesives include at least one silicone moiety and at least one hydrophilic segment. Such adhesives are applicable to securing medical devices to human skin.

Provided is a conformable composition for skin application having good formability into a predetermined shape, good conformability to skin, and shape retention after the contact with water such as excretion without loss of its shape. The conformable composition for skin application includes a reinforcing component, a rubber adhesive component, and a hydrophilic polymer compound, or the conformable composition for skin application at least includes 1 to 20 wt % a reinforcing component, 40 to 90 wt % a rubber adhesive component, and 2 to 40 wt % a hydrophilic polymer compound.

A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, vernix, and cells harvested with the amniotic fluid.

A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug.

The present disclosure is directed to an injectable composition in form of fluid gel and the use thereof to assist the tissues resection during endoscopic procedures in which it is injected in the tissue of interest to form a cushion for tissue separation. Aspects of the composition can include a gelling agent, a modifier, a salt and water. The composition can be prepared by mixing the gelling agent, modifier, at least one salt and water via continuous stirring to obtain fluid gel solutions, wherein modifier enables the said fluid gel composition to be injected into the submucosal layer of gastrointestinal tissues through endoscopic injection catheter and needle with significantly reduced injection pressure and generate a high and durable cushion for long-lasting tissue raise-up in the submucosal layer, for the application of injection assisted resection procedures.

The invention relates to porous absorbent Composite Material, which may be used e.g. in the form of a plug or tampon, for instance for controlling bleeding, wound closure, prevent tissue adhesion and/or support tissue regeneration. The invention provides a hydrophilic Self-Dispersive, fragmentable and Bio-Absorbable Porous Composite foams, suitable for packing antrum or other cavities of the body, comprising of composite of polymers, which polymer preferably comprises —C(O)—O—; NH2/3+; —OH; —CH2OCH2C(O)O— groups as functional or —CH—O— (e.g. C2H4O; C6H10O5; C6H8O6); —CH—N—O— (e.g. C8H13NO5); O—C—C— (e.g. O—CH2-CH2); —C(O)N— groups in the backbone of the polymers e.g. gelatin, chitosan, collagen, alginate, polyvinyl alcohol, polyethylene glycol, keratin, cellulose.

Pre-polymers for use as tissue sealants and adhesives, and methods of making and using thereof are provided. The pre-polymers have flow characteristics such that they can be applied through a syringe or catheter but are sufficiently viscous to remain in place at the site of application and not run off the tissue. The pre-polymers are also sufficiently hydrophobic to resist washout by bodily fluids. The pre-polymers are stable in bodily fluids; that is the pre-polymer does not spontaneously crosslink in bodily fluids absent the presence of an intentionally applied stimulus to initiate crosslinking. Upon crosslinking, the adhesive exhibits significant adhesive strength in the presence of blood and other bodily fluids. The adhesive is sufficiently elastic that it is able to resist movement of the underlying tissue. The adhesive can provide a hemostatic seal. The adhesive is biodegradable and biocompatible, causing minimal inflammatory response.

It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.

An object is to provide a preparation for forming emboli highly safe in a living body and capable of retaining and controlled-releasing an anticancer agent, occluding a blood vessel when injected into the blood vessel, unlikely to be washed out and having a controlled decomposition time (i.e., occludes a blood vessel for a while and quickly decomposes to prevent the necrosis of the entire tissues when the function is completed). The preparation for forming emboli according to the present invention comprises a solution comprising a phenolic hydroxyl group-modified polymer represented by the following formula (1): wherein P is a biocompatible polymer, A is a single bond or an —OCO—C.sub.2-C.sub.4-alkenylene group, a —CONH—C.sub.1-C.sub.4-alkylene group or an —HNCO—C.sub.1-C.sub.4-alkylene group, and X is hydrogen or a C.sub.1-C.sub.3-alkoxy group, a solution comprising at least one selected from a peroxidase, a laccase, a tyrosinase, a catalase and an iron porphyrin complex and a solution comprising hydrogen peroxide.

##STR00001##

In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.